Company profile
Fate Therapeutics, Inc. logo

Fate Therapeutics, Inc.

Pipeline6 assets

  • FT819FT819 / CD19 / iPSC-derived off-the-shelf CAR T-cell therapy / Autoimmunity
    Systemic Lupus ErythematosusPhase 1RMATUSSystemic Sclerosis (SSc)Phase 1USANCA associated Vasculitis (AAV)Phase 1US
  • FT839FT839 / CD19/CD38/CD20; CD19/CD38/BCMA/GPRC5D / Next-generation CAR T-cell therapy / Autoimmunity; Oncology
    Pan-indication without lympho-conditioning chemotherapyPhase 1USPan-indication (hematologic) without lympho-conditioning chemotherapyPhase 1US
  • FT522FT522 / CD19/CD20 / Cellular immunotherapy / Autoimmunity
    Pan-indication without lympho-conditioning chemotherapyPhase 1US
  • FT825FT825 / HER2/EGFR / iPSC-derived off-the-shelf CAR T-cell therapy / Oncology
    Solid tumorsPhase 1EnrollingUS
  • UndisclosedUndisclosed / Cellular immunotherapy / Oncology
    Solid tumorsPhase 1US
  • FT836FT836 / MICA/B/EGFR/HER2 / Next-generation CAR T-cell therapy / Oncology
    Pan-indication (solid/hematologic) without lympho-conditioning chemotherapyPhase 1US

Latest news16 items

All news

Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

SAN DIEGO, May 21, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases,

Presentation / Abstract • Phase 1ASCO poster presentation Sat, May 30, 2026, 1:30 PM CT

Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates

RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initiate in the 2 nd half of 2026 FDA selects FT819 into the CDRP ( CMC Development and Readiness Pilot)

Presentation / Abstract • Phase 1EULAR presentation Mon, Jun 1, 2026

Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases

SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases,

Presentation / Abstract • Phase 1

Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting

SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases,

Presentation / Abstract • Phase 1

Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting

SAN DIEGO, April 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases,

Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences

SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases,

Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs

FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient treated First ex- U.S. SLE patient treated with FT819 expands enrollment capacity and supports

Presentation / Abstract • Phase 1
Fate Therapeutics, Inc. • Endpoint Arena